RU2003119972A - Препараты циклодекстрина - Google Patents

Препараты циклодекстрина Download PDF

Info

Publication number
RU2003119972A
RU2003119972A RU2003119972/15A RU2003119972A RU2003119972A RU 2003119972 A RU2003119972 A RU 2003119972A RU 2003119972/15 A RU2003119972/15 A RU 2003119972/15A RU 2003119972 A RU2003119972 A RU 2003119972A RU 2003119972 A RU2003119972 A RU 2003119972A
Authority
RU
Russia
Prior art keywords
cyclodextrin
ebselen
aqueous solution
aqueous
hydroxypropyl
Prior art date
Application number
RU2003119972/15A
Other languages
English (en)
Inventor
Норио СУЗУКИ (JP)
Норио СУЗУКИ
Юкихико НАГАСЕ (JP)
Юкихико НАГАСЕ
Хитоси ЯМАУТИ (JP)
Хитоси ЯМАУТИ
Original Assignee
Дайити Фармасьютикал Ко., Лтд. (JP)
Дайити Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Лтд. (JP), Дайити Фармасьютикал Ко., Лтд. filed Critical Дайити Фармасьютикал Ко., Лтд. (JP)
Publication of RU2003119972A publication Critical patent/RU2003119972A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (13)

1. Водный жидкий лекарственный препарат, включающий эбселен и циклодекстрин.
2. Водный раствор, включающий эбселен и циклодекстрин.
3. Водный раствор в соответствии с п.2, в котором циклодекстрин представляет собой натриевую соль простого сульфобутилового эфира β–циклодекстрина или гидроксипропил-β-циклодекстрин.
4. Водный раствор по п.2 или 3, в котором молярное отношение циклодекстрина к эбселену составляет от 1:2 до 1:50.
5. Инъекционный раствор, включающий водный раствор, содержащий эбселен и циклодекстрин.
6. Инъекционный раствор по п.5, в котором циклодекстрин представляет собой натриевую соль простого сульфобутилового эфира β–циклодекстрина или гидроксипропил-β-циклодекстрин.
7. Раствор для внутривенного капельного вливания, включающий водный раствор, содержащий эбселен и циклодекстрин.
8. Раствор для внутривенного капельного вливания по п.7, в котором циклодекстрин представляет собой натриевую соль простого сульфобутилового эфира β–циклодекстрина или гидроксипропил-β-циклодекстрин.
9. Способ получения водного раствора, содержащего эбселен и циклодекстрин, включающий растворение эбселена в смешивающемся с водой органическом растворителе и отдельное растворением циклодекстрина в водном растворителе, смешивание обоих растворов, затем высушивание смеси и смешивание полученного высушенного продукта с водным растворителем.
10. Способ по п.9, в котором смешивающийся с водой органический растворитель представляет собой этанол, метанол или смесь метанола с хлороформом.
11. Высушенный препарат, включающий эбселен и циклодекстрин.
12. Высушенный препарат по п.11, в котором циклодекстрин представляет собой натриевую соль простого сульфобутилового эфира β–циклодекстрина или гидроксипропил-β-циклодекстрин.
13. Способ получения раствора, содержащего эбселен и циклодекстрин, включающий растворение эбселена в смешивающемся с водой органическом растворителе и отдельное растворение циклодекстрина в водном растворителе и смешивание обоих растворов.
RU2003119972/15A 2001-01-04 2001-12-17 Препараты циклодекстрина RU2003119972A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001000247 2001-01-04
JP2001-247 2001-01-04
JP2001-16022 2001-01-24
JP2001016022 2001-01-24

Publications (1)

Publication Number Publication Date
RU2003119972A true RU2003119972A (ru) 2004-12-27

Family

ID=26607336

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003119972/15A RU2003119972A (ru) 2001-01-04 2001-12-17 Препараты циклодекстрина

Country Status (12)

Country Link
US (1) US20040053888A1 (ru)
EP (1) EP1348432A4 (ru)
JP (1) JPWO2002055076A1 (ru)
KR (1) KR20030068203A (ru)
CN (1) CN1492760A (ru)
AR (1) AR032386A1 (ru)
BR (1) BR0116658A (ru)
CA (1) CA2434077A1 (ru)
MX (1) MXPA03006071A (ru)
NO (1) NO20033042L (ru)
RU (1) RU2003119972A (ru)
WO (1) WO2002055076A1 (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2451680C1 (ru) * 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2481830C2 (ru) * 2007-01-16 2013-05-20 Бипар Сайенсиз, Инк. Лекарственные препараты для лечения рака
WO2021054863A1 (ru) * 2019-09-18 2021-03-25 Рахимджан Ахметджанович РОЗИЕВ Стимулятор процессов репаративной регенерации тестикулярной ткани

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368484A1 (en) 1999-03-31 2000-10-05 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
CN1853627B (zh) * 2005-04-25 2011-08-10 曾慧慧 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
JP4886233B2 (ja) * 2005-07-21 2012-02-29 独立行政法人物質・材料研究機構 エブセレンの可溶化方法
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
EP1795183B1 (en) * 2005-12-09 2009-07-15 Teva Pharmaceutical Industries, Inc. Aqueous dispersions and solutions of difficult to dissolve compounds and methods of their preparation
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AU2010210636A1 (en) * 2009-02-04 2011-09-22 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
TWI830180B (zh) * 2017-06-30 2024-01-21 財團法人工業技術研究院 化合物之液體劑型的醫藥配方
WO2023240094A1 (en) * 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen
WO2024181358A1 (ja) * 2023-02-27 2024-09-06 国立大学法人東北大学 医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131113A (ja) * 1987-08-27 1989-05-24 Dai Ichi Seiyaku Co Ltd 脳障害治療剤
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US6596706B1 (en) * 1997-11-07 2003-07-22 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
AU1411600A (en) * 1998-11-30 2000-06-19 Sankyo Company Limited Immunoglobulin preparations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481830C2 (ru) * 2007-01-16 2013-05-20 Бипар Сайенсиз, Инк. Лекарственные препараты для лечения рака
RU2451680C1 (ru) * 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2021054863A1 (ru) * 2019-09-18 2021-03-25 Рахимджан Ахметджанович РОЗИЕВ Стимулятор процессов репаративной регенерации тестикулярной ткани

Also Published As

Publication number Publication date
NO20033042L (no) 2003-09-04
EP1348432A4 (en) 2005-08-10
BR0116658A (pt) 2003-12-30
CA2434077A1 (en) 2002-07-18
WO2002055076A1 (fr) 2002-07-18
JPWO2002055076A1 (ja) 2004-05-13
NO20033042D0 (no) 2003-07-02
KR20030068203A (ko) 2003-08-19
AR032386A1 (es) 2003-11-05
US20040053888A1 (en) 2004-03-18
MXPA03006071A (es) 2004-02-26
EP1348432A1 (en) 2003-10-01
CN1492760A (zh) 2004-04-28

Similar Documents

Publication Publication Date Title
RU2003119972A (ru) Препараты циклодекстрина
FI86140B (fi) Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel.
CN1653089A (zh) 有机药物与倍他环糊精衍生物配合物及其制备方法
PL195280B1 (pl) Kompleks inhibitora RAS-farnezylotransferazy o ulepszonej rozpuszczalności w wodzie i trwałości oraz kompozycja inhibitora RAS-farnezylotransferazy
WO2008031286A1 (fr) Composition pharmaceutique contenant une inclusion de cyclodextrine/paclitaxel et procédé de fabrication
JPS5835968B2 (ja) サイクロデキストリン包接化合物の製造法
ES2355133T3 (es) Complejos de inclusión de butilftalida con derivados de ciclodextrina y procedimientos para su preparación.
JP3417942B2 (ja) ニメスリドとシクロデキストリンの包接化合物
CN107661505A (zh) 桧木醇包合物及其制备方法
EP1594515A2 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
NAKAI et al. New Methods for Preparing Cyclodextrin Inclusion Compounds. II.: Effects of Heating Temperature, Water Content and Drug Properties on the Inclusion Formation
CN101574525A (zh) 亲脂性药物羟丙基-β-环糊精包合物及其制备方法
CN104001184B (zh) 高分子阿霉素键合药及其制备方法
CN106177988A (zh) 一种异槲皮素包合物的制备方法
CN101491529B (zh) 一种吡罗昔康β-环糊精包合物微丸胶囊的制备方法
JP2003012703A (ja) 無水環境下での包接複合体の製造方法
WO2004054621A1 (fr) Clathrates hydrosolubles de ziprasidone et de ses sels et procedes de preparation associes
CA1207322A (en) Process for the preparation of an inclusion complex of n-(1-phenylethyl)-3,3-diphenylpropylamine and the hydrochloride thereof respectively with cyclodextrin
CN100588427C (zh) 亲脂性药物羟丙基β环糊精包合物的制备方法
CN109847068B (zh) 一种獐牙菜苦苷的配位包合物及其制备方法和应用
CN103351342B (zh) 一种依达拉奉药物共晶及其制备方法
Caira et al. Cyclodextrin inclusion of p-hydroxybenzoic acid esters
CN106721894A (zh) 一种β‑环糊精‑山梨酸包合物及其制备方法
CN103536931A (zh) 水溶性阿奇霉素的聚β环糊精超分子包合物及其制备方法
KR100673558B1 (ko) 사이클로덱스트린 또는 이의 유도체와 부틸프탈리드의 내포 착물, 이들의 제조 방법 및 용도

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20011217